Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ADVM Adverum Biotechnologies	$2.25 -1.7%	$2.67	$1.78 ▼ $10.14	$47M	0.71	270,416 shs	173,955 shs
ARTV Artiva Biotherapeutics	$1.58 -6.0%	$2.10	$1.55 ▼ $17.31	$38.49M	N/A	171,643 shs	420,073 shs
NEUP Neuphoria Therapeutics	$6.80 +2.7%	$5.84	$2.12 ▼ $12.55	$12.78M	0.46	25,757 shs	5,769 shs
RNXT RenovoRx	$1.38	$1.17	$0.75 ▼ $1.69	$50.47M	1.32	94,432 shs	163,041 shs

Investing Strategies To Help Grow Your Retirement Income

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ADVM Adverum Biotechnologies	-1.75%	-8.54%	-0.88%	-55.88%	-65.86%
ARTV Artiva Biotherapeutics	-5.95%	-20.20%	-21.00%	-63.00%	+157,999,900.00%
NEUP Neuphoria Therapeutics	+2.72%	-0.29%	+22.97%	+26.39%	+679,999,900.00%
RNXT RenovoRx	0.00%	+6.15%	+13.11%	+43.75%	+0.73%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ADVM Adverum Biotechnologies	3.9371 of 5 stars	3.4	1.0	0.0	4.8	1.8	2.5	0.6
ARTV Artiva Biotherapeutics	2.977 of 5 stars	3.5	0.0	0.0	0.0	3.3	1.7	1.3
NEUP Neuphoria Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
RNXT RenovoRx	2.1988 of 5 stars	3.5	5.0	0.0	0.0	0.0	1.7	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ADVM Adverum Biotechnologies	2.80	Moderate Buy	$26.40	1,073.33% Upside
ARTV Artiva Biotherapeutics	3.00	Buy	$17.80	1,026.58% Upside
NEUP Neuphoria Therapeutics	3.00	Buy	$21.00	208.82% Upside
RNXT RenovoRx	3.00	Buy	$7.25	425.36% Upside

Current Analyst Ratings Breakdown

Latest NEUP, ARTV, RNXT, and ADVM Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/11/2025	ARTV Artiva Biotherapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Buy	$12.00
6/5/2025	RNXT RenovoRx	Ascendiant Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$11.00 ➝ $11.50
5/19/2025	RNXT RenovoRx	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$3.00 ➝ $3.00
5/15/2025	ADVM Adverum Biotechnologies	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Sector Perform ➝ Sector Perform	$5.00 ➝ $4.00
5/15/2025	ADVM Adverum Biotechnologies	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$33.00 ➝ $33.00
5/15/2025	ADVM Adverum Biotechnologies	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$30.00 ➝ $30.00
5/15/2025	ARTV Artiva Biotherapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$23.00 ➝ $18.00
4/28/2025	RNXT RenovoRx	Ascendiant Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$9.00 ➝ $11.00
4/17/2025	ADVM Adverum Biotechnologies	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$40.00 ➝ $33.00
4/16/2025	ADVM Adverum Biotechnologies	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Sector Perform ➝ Sector Perform	$10.00 ➝ $5.00
4/16/2025	ADVM Adverum Biotechnologies	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$30.00 ➝ $30.00

(Data available from 6/21/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ADVM Adverum Biotechnologies	$1M	47.00	N/A	N/A	$3.40 per share	0.66
ARTV Artiva Biotherapeutics	$250K	153.96	N/A	N/A	$7.68 per share	0.21
NEUP Neuphoria Therapeutics	$10K	1,278.40	N/A	N/A	$15.85 per share	0.43
RNXT RenovoRx	$40K	1,261.67	N/A	N/A	$0.19 per share	7.26

Compare Profitability & Earnings

Company	Net Income	EPS	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ADVM Adverum Biotechnologies	-$130.93M	-$6.40	N/A	N/A	N/A	-130.53%	-66.31%	8/11/2025 (Estimated)
ARTV Artiva Biotherapeutics	-$65.37M	N/A	N/A	N/A	N/A	-75.95%	-39.51%	6/23/2025 (Estimated)
NEUP Neuphoria Therapeutics	-$15.49M	N/A	N/A	N/A	N/A	N/A	N/A	N/A
RNXT RenovoRx	-$8.81M	-$0.40	N/A	N/A	N/A	-119.58%	-88.01%	8/12/2025 (Estimated)

Latest NEUP, ARTV, RNXT, and ADVM Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/20/2025	Q3 2025	NEUP Neuphoria Therapeutics	-$0.47	$6.55	+$7.02	$6.55	N/A	$15.00 million
5/15/2025	Q1 2025	RNXT RenovoRx	-$0.08	-$0.08	N/A	-$0.08	$0.23 million	$0.20 million
5/8/2025	Q1 2025	ARTV Artiva Biotherapeutics	-$0.68	-$0.83	-$0.15	-$0.83	N/A	N/A
4/15/2025	Q4 2024	ADVM Adverum Biotechnologies	-$1.34	-$1.96	-$0.62	-$1.96	N/A	N/A
3/31/2025	Q4 2024	RNXT RenovoRx	-$0.12	-$0.13	-$0.01	-$0.12	$0.17 million	$0.04 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ADVM Adverum Biotechnologies	N/A	N/A	N/A	N/A	N/A
ARTV Artiva Biotherapeutics	N/A	N/A	N/A	N/A	N/A
NEUP Neuphoria Therapeutics	N/A	N/A	N/A	N/A	N/A
RNXT RenovoRx	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ADVM Adverum Biotechnologies	N/A	3.57	3.57
ARTV Artiva Biotherapeutics	N/A	13.93	13.93
NEUP Neuphoria Therapeutics	N/A	11.01	11.01
RNXT RenovoRx	N/A	9.07	9.07

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ADVM Adverum Biotechnologies	48.17%
ARTV Artiva Biotherapeutics	N/A
NEUP Neuphoria Therapeutics	15.90%
RNXT RenovoRx	3.10%

Insider Ownership

Company	Insider Ownership
ADVM Adverum Biotechnologies	6.00%
ARTV Artiva Biotherapeutics	21.40%
NEUP Neuphoria Therapeutics	0.69%
RNXT RenovoRx	9.13%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ADVM Adverum Biotechnologies	190	20.89 million	19.64 million	Optionable
ARTV Artiva Biotherapeutics	81	24.36 million	19.15 million	N/A
NEUP Neuphoria Therapeutics	N/A	1.88 million	1.87 million	N/A
RNXT RenovoRx	6	36.57 million	33.23 million	Not Optionable

NEUP, ARTV, RNXT, and ADVM Headlines

Recent News About These Companies

Insider Buying: RenovoRx, Inc. (NASDAQ:RNXT) Insider Buys 21,000 Shares of Stock

June 10, 2025 | insidertrades.com

Insider Buying: RenovoRx, Inc. (NASDAQ:RNXT) Insider Acquires 21,000 Shares of Stock

June 9, 2025 | marketbeat.com

RenovoRx (NASDAQ:RNXT) Stock Rating Upgraded by Wall Street Zen

June 7, 2025 | marketbeat.com

RenovoRx (RNXT) PT Raised to $11.50 by Ascendiant on Strong Q1 2025 Results

June 6, 2025 | finance.yahoo.com

RenovoRx (NASDAQ:RNXT) Given New $11.50 Price Target at Ascendiant Capital Markets

June 5, 2025 | marketbeat.com

Ascendiant Capital relève l’objectif de cours de l’action RenovoRx à 11,50€

June 5, 2025 | fr.investing.com

Earnings call transcript: RenovoRx Q1 2025 revenue exceeds expectations

May 17, 2025 | investing.com

RenovoRx, Inc. (NASDAQ:RNXT) Q1 2025 Earnings Call Transcript

May 17, 2025 | msn.com

RenovoRx Inc (RNXT) Q1 2025 Earnings Call Highlights: Promising Revenue Growth and Clinical ...

May 16, 2025 | finance.yahoo.com

Le BPA de RenovoRx a dépassé les attentes, le CA en dessous des prévisions

May 15, 2025 | fr.investing.com

Transcription des résultats : le chiffre d’affaires de RenovoRx au T1 2025 dépasse les attentes

May 15, 2025 | fr.investing.com

RenovoRx, Inc. (RNXT) Q1 2025 Earnings Conference Call Transcript

May 15, 2025 | seekingalpha.com

RenovoRx, Inc. (RNXT) Reports Q1 Loss, Lags Revenue Estimates

May 15, 2025 | zacks.com

RenovoRx Reports First Quarter 2025 Financial Results and Business Highlights

May 15, 2025 | businesswire.com

Earnings Preview For RenovoRx

May 14, 2025 | benzinga.com

RenovoRx to Participate in Fireside Chat at A.G.P. Virtual Healthcare Company Showcase on May 21st

May 14, 2025 | finance.yahoo.com

U.S. Patent Office Issues New Patent to RenovoRx for Novel Trans-Arterial Micro-Profusion (TAMP™) Therapy Platform

May 6, 2025 | finance.yahoo.com

Johns Hopkins Medicine lance le recrutement de patients pour l'essai clinique de phase III TIGeR-PaC en cours de RenovoRx

April 30, 2025 | zonebourse.com

Johns Hopkins Medicine lance le recrutement de patients pour l'essai clinique de phase III en cours de Renovorx sur le Tiger-Pac

April 29, 2025 | zonebourse.com

Johns Hopkins rejoint l’essai TIGeR-PaC de RenovoRx sur le cancer du pancréas

April 29, 2025 | fr.investing.com

Johns Hopkins Medicine Initiates Patient Enrollment for RenovoRx’s Ongoing Phase III TIGeR-PaC Clinical Trial

April 29, 2025 | finance.yahoo.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

NEUP, ARTV, RNXT, and ADVM Company Descriptions

Adverum Biotechnologies NASDAQ:ADVM

$2.25 -0.04 (-1.75%)

Closing price 06/20/2025 04:00 PM Eastern

Extended Trading

$2.25 0.00 (0.00%)

As of 06/20/2025 04:04 PM Eastern

Adverum Biotechnologies, Inc., a clinical-stage company, develops gene therapy product candidates to treat ocular diseases. Its lead product candidate is ixoberogene soroparvovec (ADVM-022), a single intravitreal injection gene therapy candidate used for the treatment of patients with wet age-related macular degeneration and diabetic macular edema which is in phase 2 clinical trials. The company is developing ADVM-062 (AAV.7m8-L-opsin), a novel gene therapy product candidate for the treatment of blue cone monochromacy via a single IVT injection. Adverum Biotechnologies, Inc. has license and collaboration agreements with University of California; GenSight Biologics; Lexeo Therapeutics; and Virovek, Inc. The company was formerly known as Avalanche Biotechnologies, Inc. and changed its name to Adverum Biotechnologies, Inc. in May 2016. Adverum Biotechnologies, Inc. was incorporated in 2006 and is headquartered in Redwood City, California.

Artiva Biotherapeutics NASDAQ:ARTV

$1.58 -0.10 (-5.95%)

Closing price 06/20/2025 04:00 PM Eastern

Extended Trading

$1.63 +0.05 (+3.16%)

As of 06/20/2025 07:43 PM Eastern

Artiva Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. The company's lead product candidate is AB-101, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody-associated vasculitis subtypes granulomatosis with polyangiitis/microscopic polyangiitis, systemic lupus erythematosus, and B-cell-non-Hodgkin lymphoma. It also develops AB-201, an allogeneic anti- human epidermal growth factor receptor 2 chimeric antigen receptor (CAR)-NK cell product candidate; and AB-205, an allogeneic anti-CD5 CAR-NK cell product candidate. The company was incorporated in 2019 and is headquartered in San Diego, California.

Neuphoria Therapeutics NASDAQ:NEUP

$6.80 +0.18 (+2.72%)

As of 06/20/2025 03:58 PM Eastern

Neuphoria Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. It focuses on developing BNC210, an oral drug designed for the acute treatment of social anxiety disorder (SAD) and the chronic treatment of post-traumatic stress disorder (PTSD) by selectively targeting the a7 nicotinic acetylcholine receptor. The company was founded on December 23, 2024 and is headquartered in Burlington, MA.

RenovoRx NASDAQ:RNXT

$1.38 0.00 (0.00%)

Closing price 06/20/2025 04:00 PM Eastern

Extended Trading

$1.38 0.00 (-0.36%)

As of 06/20/2025 06:47 PM Eastern

RenovoRx, Inc., a clinical-stage biopharmaceutical company, focuses on developing proprietary targeted combination therapies to improve therapeutic outcomes for cancer patients undergoing treatment. Its lead product candidate is RenovoGem, an oncology drug-device combination product, consisting of intra-arterial gemcitabine and RenovoCath that is in Phase III clinical trials for the locally advanced pancreatic cancer. The company has a research collaboration with Imugene Limited to deliver oncolytic virus therapy for the treatment of difficult-to-access tumors. RenovoRx, Inc. was founded in 2009 and is headquartered in Los Altos, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time